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Abstract
The aim of the study was to determine the antiangiogenic efficacy of vatalanib, sunitinib, and AMD3100 in an animal
model of human glioblastoma (GBM) by using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
and tumor protein expression analysis. Orthotopic GBM-bearing animals were randomly assigned either to con-
trol group or vatalanib, sunitinib, and AMD3100 treatment groups. Following 2 weeks of drug treatment, tumor
growth and vascular parameters were measured using DCE-MRI. Expression of different angiogenic factors in tumor
extracts was measured using a membrane-based human antibody array kit. Tumor angiogenesis and invasion were
determined by immunohistochemistry. DCE-MRI showed a significant increase in tumor size after vatalanib treat-
ment. AMD3100-treated group showed a significant decrease in a number of vascular parameters determined by
DCE-MRI. AMD3100 significantly decreased the expression of different angiogenic factors compared to sunitinib
or vatalanib; however, there were no significant changes in vascular density among the groups. Sunitinib-treated
animals showed significantly higher migration of the invasive cells, whereas in both vatalanib- and AMD3100-treated
animals the invasive cell migration distance was significantly lower compared to that of control. Vatalanib and
sunitinib resulted in suboptimal therapeutic effect, but AMD3100 treatment resulted in a significant reduction in
tumor growth, permeability, interstitial space volume, and invasion of tumor cells in an animal model of GBM.
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Introduction
Glioblastomas (GBMs) are tumors characterized by hypervascularity
and active neovascularization. Various antiangiogenic strategies have
been used as adjuvant treatment to normalize blood vessels and control
aberrant angiogenesis [1–5]. However, antiangiogenic therapies have
been shown to provide only a short-term clinical benefit for about
few weeks or months [6–9]. A typical example of such acquired treat-
ment resistance is seen with the use of drugs targeting vascular endo-
thelial growth factor (VEGF) and VEGF receptor (VEGFR) pathway.
In our previous work, we observed an increase in the expression of
various angiogenic factors, and a significant increase in the number
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of dilated blood vessels following a 2-week treatment with PTK787
(small molecule protein kinase inhibitor that inhibits angiogenesis).
Antiangiogenic treatment involves modulation of a wide range of
molecular targets [10]. A novel antiangiogenic strategy could be based
on the use of broader tyrosine kinase inhibitors that affect not only
the VEGFR tyrosine kinase but also other tyrosine kinases as well.
One such drug is sunitinib, a small molecule multitarget receptor
tyrosine kinase inhibitor, that is known to inhibit signaling through
multiple receptors such as platelet-derived growth factor receptors
(PDGFRs), VEGFRs, c-KIT, colony-stimulating factor-1 receptor,
and fetal liver kinase 3–internal tandem duplication (FLT3-ITD) [11].
Another possible mechanism of antiangiogenic treatment resis-
tance may involve stromal cell–derived factor 1α (SDF-1α) pathway–
mediated mobilization of bone marrow (BM)–derived endothelial
progenitor cells through CXCR4 receptors on these cells [9,10]. In-
hibition of the SDF-1α/CXCR4 axis might prevent the accumulation
of endothelial progenitor cells at the tumor site and potentially block
vasculogenesis. AMD3100, a potent CXCR4 receptor antagonist,
mobilizes CD34+ hematopoietic stem cells into peripheral circulation
[12]. Recent investigations have revealed that a continuous treat-
ment with AMD3100 or similar CXCR4 receptor antagonist blocks
vasculogenesis, leading to growth inhibition [12,13].
Currently, the efficacy of antiangiogenic therapy is being studied
using invasive techniques. The use of noninvasive techniques that
allow monitoring of dynamic changes in the tumors after the treat-
ment would allow for better understanding of treatment efficacy
and may be more valuable in effectively modifying treatment strat-
egies. Magnetic resonance imaging (MRI) is one of the noninvasive
imaging modalities that can be used to monitor dynamic changes
in tumors during treatments and subgroup of glioma [14]. Many
preclinical and clinical studies have shown that dynamic contrast-
enhanced MRI (DCE-MRI) can be useful in assessing tumor vas-
cular parameters and in predicting tumor angiogenesis and tumor
response following antiangiogenic therapy [15,16]. DCE-MRI tech-
nique measures the pharmacokinetic uptake and washout of an MRI
contrast agent within the intracellular and extracellular spaces of
tumor tissues, and it can be used to evaluate the vascular forward
permeability transfer constant (K trans), backflow transfer constant
(K b), plasma volume of tumor blood volume (V p), and interstitial
space volume (V e). These parameters have been shown to correlate
with tumor perfusion and angiogenesis [17,18].
The purpose of the study was to determine the effects of anti-
angiogenic treatment on tumor growth in a U251 animal model
using vatalanib, sunitinib, and AMD3100 by using DCE-MRI vascular
parameters and changes in protein expression.
Materials and Methods
Ethics Statement
Animal experiments were performed according to the NIH
guidelines, and the experimental protocol was approved by the
Institutional Animal Care and Use Committee of the Henry Ford
Health System.
Animal Model
Thirty nude rats (RNU nu/nu), 6 to 8 weeks of age and 150 to
170 g of weight (Charles River Laboratories, Inc, Frederick, MD),
were included in the study. Orthotopic glioma was created by injecting
4 × 105 U251 cells suspended in 5 μl of saline at 3 mm to the
right and 1 mm anterior to the bregma as described in our previous
publications [10,19,20].
Treatment Schedules
Animals were randomly assigned to either the drug treatment
(vatalanib, n = 5; sunitinib, n = 8; and AMD3100, n = 7) or the con-
trol group (n = 10). The control group was treated with the vehicle
[cremophor EL/DMSO/phosphate-buffered saline (PBS) at 1:1:8]
either by oral gavage (n = 5) or by intraperitoneal injection (n = 5).
Vatalanib (LC Laboratories, Woburn, MA) was prepared for oral
administration using the vehicle (cremophor EL/DMSO/PBS at
1:1:8) and was administered orally by gavage, once a day at a dose
of 50 mg/kg per feeding for 2 weeks. Sunitinib (LC Laboratories)
was dissolved in the vehicle and administered by intraperitoneal
injection at a dose of 80 mg/kg per day for 2 weeks. AMD3100
(TORCIS Bioscience, Minneapolis, MN) was dissolved in distilled
water and injected subcutaneously at a dose of 5 mg/kg per day
(divided into two doses per day) for 2 weeks. Drug administration
started 8 days after tumor implantation and continued for two weeks
(5 days/week). Twenty-two days after tumor implantation, animals
underwent in vivo DCE-MRI followed by euthanasia and collection
of brain tissue.
In Vivo MRI
Animals were anesthetized with 2% isoflurane in oxygen carrier gas
and secured to a customized cradle. A 26-g dental catheter was inserted
into a tail vein to facilitate the injection of contrast agents. The animal
body temperature was maintained at 37.0°C during scan within the
MRI magnet. MRIs were obtained with a 3T clinical system (Signa
Excite; GE Healthcare, Wauwatosa, WI) using 50 mm × 108 mm
RF rung length small animal imaging coil (Litzcage small animal imag-
ing system; Doty Scientific Inc, Columbia, SC). Precontrast and post-
contrast T1-weighted images (T1WIs), multiecho T2-weighted images
(T2WIs), and three-dimensional spoiled gradient echo (3D SPGR)
images of the tumor-bearing brain were acquired before (four to five
sequences) and sequentially up to 20 minutes following IV injection
of gadolinium-diethylenetriamine pentaacitic acid (Gd-DTPA). The
following parameters were used to acquire the images. For T1WIs,
repetition time (TR) = 625 ms, echo time (TE) = 15 ms using a 160 ×
128 matrix, field of view (FOV) = 35 mm, and number of excitation
(NEX) = 4; effective slice thickness was 1 mm, and 15 slices were
imaged. For multiecho T2WIs, TR = 2100 ms, TE = 15, 30, 45,
and 60 using a 160 × 128 matrix, FOV = 35 mm, and NEX = 2. -
Effective slice thickness was 1 mm, and 15 slices were imaged. Multi-
echo T2WIs were used to create T2 maps. To generate T1 maps from
precontrast images, 3D SPGR images with multiple flip angles of 2°,
4°, 8°, 12°, 15°, 20 °, 25 °, 30°, and 35° were acquired. The following
parameters were used to acquire the 3D SPGR images: TR = 5.65 ms,
TE = 1.35 ms using a 128 × 128 matrix, FOV = 60 × 60 × 18 mm3,
and NEX = 1. Effective slice thickness was 1.5 mm. To obtain dynamic
postcontrast 3D SPGR images, a fixed flip angle of 30° was used.
Acquisition of SPGR images started before the administration of
contrast to have baseline T1 signals.
Kinetic Analysis
DCE-MRI was performed using a transverse T1W 3D SPGR
acquisition that consisted of obtaining precontrast (four to five se-
quences) and dynamic postcontrast images up to 20 minutes after
the contrast injection. We used the DCE-MRIs and the following
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Patlak model to estimate the transfer constants K trans and K b, plasma
volume of tumor blood volume (V p), and interstitial space volume
(V e) according to the following equation [17,18]:
CtðtÞ = K trans
Z t
0
CpðτÞeKbðtτÞdτ + VpCpðtÞ:
C t(t) and Cp(t) are the tissue and the plasma concentrations over
time, respectively. K trans is the unidirectional transfer rate constant
of the contrast from plasma across the vascular endothelium and
blood-brain barrier into the interstitial fluid. K b is the reverse trans-
fer rate constant from the extravascular compartment to the vascular
compartment. V p is the fractional volume of the contrast agent vascu-
lar distribution space, usually thought to be the plasma distribution
space. If the transvascular transfer of the contrast agent is passive,
the two rate constants are related through the interstitial space volume
fraction: V e = K
trans/K b. Our recent publication shows the validity of
this method [17]. The K trans, K b, V p, and V e of the tumors (both
treated and control) were determined by drawing irregular regions of
interests (ROIs) encompassing the whole tumor. An investigator
blinded to both treated and untreated animals drew the ROIs and
determined the values.
Measurement of Tumor Volume
Postcontrast T1WIs were used to determine the volume of the
tumor in each animal. Two investigators blinded to the treatment
groups determined the volume by drawing irregular ROIs around
the tumor and multiplying the area with the slice thickness.
Protein Extraction from Tumors
Animals were killed, and brain tissues were collected after perfusion
using ice-cold 1× PBS. The tumor-bearing hemisphere and contra-
lateral brain were separated, snap frozen, and stored at −80°C. On
the day of protein extraction, tumor was carefully separated from the
surrounding brain tissues and total protein from the tumor was ex-
tracted using mechanical pulverization over dry ice and 2× RayBio cell
lysis buffer according to the manufacturer’s instructions (RayBiotech,
Inc, Norcross, GA). Total protein concentration was measured by
Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA) using
BSA as a standard.
Protein Analysis
The levels of specific cytokines/factors within the tumor-extracted
total protein were analyzed using a custom-designed membrane-based
human cytokine antibody array kit from RayBiotech, Inc accord-
ing to the recommended method of the vendor. The membrane-
based quantitative antibody array has a standard membrane spotted
with 20 cytokine capture antibodies, and the detection is based on
chemiluminescent labeling. Positive signals were detected with chemi-
luminescent detection solution using Multispectral Imaging System
(Carestream, Rochester, NY). Images were analyzed using ImageJ soft-
ware (NIH). The density of each signal was normalized using positive
controls included on the membrane as well as corresponding values in
the control animals. The following factors were analyzed: angiogenin,
angiostatin, angiopoietin-1, angiopoietin-2, granulocyte colony stimu-
lating factor (G-CSF), PDGF-AA, PDGFR-A, RANTES, basic fibro-
blast growth factor (bFGF), epidermal growth factor (EGF), EGF
receptor, insulin growth factor-1 (IGF-1), matrix metalloproteinase-9
(MMP-9), SDF-1α, Tie-1, Tie-2, VEGF-A, VEGF-C, VEGFR2, and
VEGFR3. Table 1 shows the relative characteristics of the growth fac-
tors in angiogenesis.
Protein Estimation by ELISA
MMP-2 and hypoxia inducible factor-1 (HIF-1α) were quantified
as a marker for tumor infiltration and hypoxia, respectively. MMP-2
and HIF-1α levels were determined in the vehicle and drug-treated
tumors using ELISA kit according to the manufacturer’s instructions
(RayBiotech, Inc). All values were normalized to the corresponding
values in the control animals.
Histopathology
Animals used for the histologic analysis were killed and perfused
by intracardiac injection of 100 ml of PBS, followed by 3% para-
formaldehyde. Brains were collected and fixed in 3% paraformalde-
hyde containing 3% sucrose. Tissue sections were prepared from
either frozen or paraffin preparations. Standard histochemical staining
procedures were performed as recommended by the suppliers of pri-
mary antibodies. Our histochemical analysis concentrated on the
markers of neovascularization, invasion, and human-specific cells.
Sections were stained to determine neovascularization by using von
Willebrand factor (vWF; Dako, Carpinteria, CA) and invasion of
tumor cells by targeting human-specific major histocompatibility
complex-1 (MHC-1), cluster of differentiation 44 (CD44), and
MMP-2 (all antibodies were from Lab Vision, Kalamazoo, MI).
CD44-positive cells are considered as highly migratory, tumor stem
cell like, and resistant to drug treatments [21–23]. MMP-2 is known
for its involvement in a breakdown of extracellular matrix that makes
the way for tumor invasion. MHC-1 and MMP-2 were double stained
to determine if the migration of human cells (2° IgG + fluorescein
isothiocyanate) was related to MMP-2 (2° IgG + rhodamine)–positive
areas. Consecutive sections were also double stained with vWF
(2° IgG + rhodamine) and CD44 (2° IgG + rhodamine) to determine
if the invasive cells migrated at the regions of neovascularization.
Evaluation of Microvessel Density
Microvessels were detected by immunohistochemical staining with
vWF. vWF staining is well established for determining neovascularization
Table 1. Angiogenesis-Related Growth Factors in GBM Tumors.
Growth Factor–Related Angiogenesis Stimulation Inhibition
Angiogenin + −
Angiostatin − +
Angiopoietin + −
Tie-1 and Tie-2 + −
G-CSF + −
bFGF + −
SDF-1 + −
RANTES + −
VEGF/VEGFR + −
PDGF + −
EGF + −
EGF receptor + −
MMP-9 − +
IGF-1 + −
MMP-2 + −
HIF-1α + −
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in different lesions [24–26]. Each cell positive for vWF was considered
to be a microvessel. Five “hot spots” (area with highest vessel concen-
tration) from each slide were identified, and vWF-positive areas were
counted by two independent observers. The total area of histologic sec-
tion viewed on microphotography was noted, and microvessel density
(MVD) was calculated as previously described [27].
Tumor Cell Migration and Invasion
The distance between the MHC-1–positive cells and the margin of
the primary tumor mass was evaluated using low, ×4 to ×10, image
magnification. The tumor periphery was confirmed on high mag-
nification before all measurements. An irregular line was drawn at
the most peripheral part of the tumor that showed continuation to
the primary tumor mass. Any MHC-1–positive cells away from the
drawn line were considered invasive cells away from the primary tumor
mass. A perpendicular line was drawn from the invasive tumor cells or
tumor foci (center of the foci) to the drawn line at the tumor periphery,
and the distance was noted. Distance from migrated individual cell or
distal tumor foci to the periphery of the primary tumor mass was de-
termined, and the average values were calculated. The analysis was done
using the software supplied by the vendor (ToupView Software, Irvine,
CA). The average distance between the MHC-1–positive cells and the
tumor margin was determined for vatalanib, sunitinib, AMD3100, and
vehicle-treated tumors. Consecutive sections of the tumor were stained to
determine the expression of vWF, CD44, and MMP-2 at the
corresponding sites of tumor cell invasion.
Statistical Analysis
Comparison between drug and vehicle-treated groups was done
by using one-way analysis of variance with protected least significant
difference (PLSD) post hoc test. All data are expressed as means ±
SEM. Any P value of <.05 was considered significant.
Results
Effects of Vatalanib, Sunitinib, and AMD3100 on
Tumor Growth
All animals showed measurable and well-enhanced tumor in the
right brain hemisphere by day 22, and all tumors were detected by
postcontrast T1WIs (Figure 1A). Tumor volumes measured from
postcontrast T1WIs are shown in Figure 1C . Compared to the con-
trol, tumors treated with vatalanib showed significantly increased
volume following treatment (P < .01). However, both sunitinib and
AMD3100 treatments resulted in a nonsignificant decrease in the
tumor size, compared to the vehicle treatment (P = .25 and P = .45,
respectively). T2WIs confirmed the changes in the tumor size as seen
on T1WIs (Figure 1B). However, no significant differences in T2
values were observed between the control and drug-treated groups
(Figure 1D), indicating the absence of necrosis or edema following
drug treatments.
DCE-MRI Vascular Parameter Analysis
The following vascular parameters were estimated using DCE-MRI
in vehicle and drug-treated tumors: K trans, K b, V p, and V e (Figure 2).
Figure 1. Effect of antiangiogenic treatment in U251 tumor determined by MRI. Postcontrast T1WI (A) and T2WI changes (B) after
2 weeks of antiangiogenic treatment with vatalanib, sunitinib, and AMD3100; tumor volumes measured after vehicle and drug treat-
ment (C); T2 maps of U251 tumors following antiangiogenic therapy showed no significant edema or necrosis compared to the vehicle-
treated tumor (D). *P < .05. All tumors were in the right hemisphere.
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There was no significant difference observed for V p among the groups
treated with vatalanib, sunitinib, AMD3100, and vehicle. Vatalanib,
sunitinib, and AMD3100 treatments resulted in a decrease in tumor
K trans (whole tumor) compared to the vehicle treatment. However,
a significant decrease in the K trans value was only observed for the
tumors treated with AMD3100 (P < .01). Similarly, a decrease in K b
was observed in tumors treated with either vatalanib or sunitinib or
AMD3100, compared to vehicle treatment. However, the decrease
was only significant for the AMD3100 treatment group (P < .0001).
V e was increased after vatalanib treatment compared to vehicle treatment.
However, only AMD3100 treatment significantly (P < .001) reduced V e
in the tumors compared to the vehicle treatment. The DCE-MRI results
indicate that there was a significant decrease in the tumor vascular per-
meability after AMD3100 treatment, compared to the vehicle treatment.
However, vatalanib treatment resulted in a net increase in the tumor
volume and interstitial space, as indicated by the increase inV e compared
to vehicle treatment. Compared to the control group, there was no
significant change in the tumor growth and vascular parameters after
sunitinib treatment. The experiment results indicate that AMD3100-
treated tumors showed greater antitumor responses on DCE-MRI,
compared to the sunitinib- and vatalanib-treated tumors.
Protein Array
The results are summarized in Figure 3. An increase in the ex-
pression of angiostatin, an antiangiogenic protein, was observed in
the tumors treated with vatalanib, sunitinib, and AMD3100 com-
pared to vehicle treatment; however, this difference reached the
significance in the animals treated with sunitinib. Changes in the
expression levels of proangiogenic factors in response to vatalanib,
sunitinib, and AMD3100 are shown in Figure 3. AMD3100 treat-
ment resulted in a net decrease in the expression of most pro-
angiogenic factors tested compared to the vehicle treatment, with
the significant decrease seen in the expression of IGF-1, VEGFR2,
and VEGF-C. Sunitinib treatment resulted in an increase in the
expression of proangiogenic growth factors including bFGF, PDGF-
AA, EGF, SDF-1, angiopoietin-1 and angiopoietin-2, and Tie-1 and
Tie-2, compared to vehicle treatment. Similarly, vatalanib treatment
led to an increased expression of various proangiogenic growth
factors compared to vehicle treatment. The expression of G-CSF
was significantly higher after vatalanib treatment, compared to
vehicle treatment, whereas sunitinib and AMD3100 decreased the
expression of G-CSF, compared to that of vehicle-treated animals
(Figure 3).
Histologic Analysis
Tumor angiogenesis and MVD. Tumor neovascularization was
assessed by quantification of MVD. Histologic evaluation of MVD fol-
lowing 2 weeks of treatments showed no significant differences among
Figure 2. MRI vascular parametric analysis after antiangiogenic therapy. The upper panel shows maps from a representative case
showing tumor plasma volume (V p), vascular forward transfer constant (K
trans), backflow transfer constant (K b), and interstitial space
volume (V e). The middle and lower panels show quantitative estimations of V p, K
trans, K b, and V e after the drug treatment. Note the
significant decreased K trans, K b, and V e in tumors treated with AMD3100. *P < .05. All tumors were in the right hemisphere.
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different groups of animals treated with either one of the drugs or
vehicle (Figure 4).
Tumor cell migration. To identify implanted tumor human
origin cells, we have used antibodies specific for human MHC-1
molecule. The distance of the MHC-1–positive cells’ location from
the primary tumor mass was measured and used as an assessment of
tumor invasiveness and the ability of tumor cells to migrate away
from the primary tumor. Tumors in the drug treatment group exhib-
ited multiple foci of human cells located away from the margin of the
primary tumors. However, on quantitative evaluation, the average
distance migrated by the tumor cells was significantly higher in the
sunitinib-treated tumors (P < .0001; Figure 5). However, treatment
with vatalanib and AMD3100 resulted in a statistically significant
reduction in the tumor cell migration compared to vehicle treatment
(P < .0001; Figure 5).
Co-expression of markers. Co-expression of CD44 (tumor cell
migration), MMP-2 (infiltration), and vWF (neovascularization)
in the vicinity of MHC-1–positive cells following treatment with
vatalanib, sunitinib, and AMD3100 is shown in Figure 6. Under all
treatment conditions, MHC-1–positive cells (green in Figure 6, upper
panel) were at the close proximity with the areas where expression
of MMP-2 was detected (red areas). However, when consecutive sec-
tions were stained for vWF and CD44 markers, not all the areas that
showed MHC-1–positive cells were CD44 (red in Figure 6, lower
panel) positive. In addition, except in few areas, most of the CD44-
positive cells were seen to be away from vWF-positive areas. However,
a few CD44-positive cells were seen in the lining of vWF-positive
Figure 3. Quantitative analysis of tumor growth factors using protein array kit and ELISA. AMD3100 treatment resulted in a net decrease
in the expression of most proangiogenic factors compared to the vehicle treatment. G-CSF expression was significantly increased after treat-
ment with vatalanib compared to the vehicle-treated tumor. Note the significant decrease of VEGFR2 in vatalanib-treated tumors. *P < .05.
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areas (yellow arrows), which may indicate the incorporation of tumor
cells into neovessels.
Discussion
The interpretation of the efficacy of antiangiogenic drug treatment is
currently limited by our incomplete understanding of tumor vascular
physiology. Hence, it would be worthwhile to combine the available
imaging and histologic techniques in understanding and predicting
the efficacy of antiangiogenic therapy. The goal of this study was
to determine the antiangiogenic efficacy of vatalanib, sunitinib, and
AMD3100 in orthotopic U251 tumors using the dual approach.
DCE-MRI was used as a noninvasive method to measure the changes
in vascular parameters following antiangiogenic therapy. We also evalu-
ated the changes in the expression of tumor factors following anti-
angiogenic treatment. Our results indicate that AMD3100 treatment
resulted in a significant reduction of tumor growth, whereas vatalanib
treatment significantly increased tumor growth as measured by MRI,
which is in good agreement with our previous reports [10].
At present, conventional morphologic imaging is being used to
estimate tumor response following antiangiogenic therapy. However,
this technique is limited by the difficulty in distinguishing tumor- versus
treatment-related changes. In addition, relevant clinical information
can only be obtained weeks or months after treatment initiation [28].
DCE-MRI is an exciting and promising imaging tool that allows
for characterization of the vascular changes by measuring specific physi-
ological characteristics inside the tumor [29]. DCE-MRI could po-
tentially provide clinically relevant information much earlier than the
conventional imaging and would be more efficient in monitoring treat-
ment response. AMD3100 treatment resulted in a decrease in K trans,
K b, and V e, indicating a decrease in neovascularity (permeability),
interstitial space volume, and blood volume, respectively. These find-
ings indicate a net decrease in the angiogenesis after treatment with
AMD3100. Vatalanib treatment decreased whole tumor K trans, K b,
and V p but increased V e. Although the changes were not significant
compared to that of vehicle-treated tumors, the increase in V e follow-
ing drug treatment would indicate an increase in extracellular space.
The increase in extracellular space may be the result of disorganization
of tumor interstitial space because of neovascularization. However,
presence of low level central necrosis cannot be ruled out. Sunitinib
treatment nonsignificantly increased V p that indicates an increase in
tumor blood plasma volume, which could be due to increased neo-
vascularization; however, slightly decreased K trans (permeability) indi-
cates an organized vasculature.
The expression of various tumor growth factors following anti-
angiogenic therapy was also evaluated. Vatalanib treatment in U251
tumors increased the expression of many proangiogenic growth factors
including G-CSF, SDF-1α, angiopoietin-1 and angiopoietin-2, angio-
genin, and MMP-2. The paradoxical increase in the angiogenic signal
Figure 4. Histologic analysis of vascular density. Immunohisto-
chemistry staining with anti-vWF antibody shows tumor neo-
vascularization (upper panel; original magnification, ×40) with or
without antiangiogenic treatments. Quantitative estimation of
MVD by counting vWF-positive areas revealed significant changes
inMVD after vatalanib, sunitinib, or AMD3100 treatments compared
to the vehicle-treated tumor (lower panel). However, note the dilated
and irregular vessels following treatments.
Figure 5. Migration of human marker-positive cells. Representa-
tive images of tumor sections were stained with invasion marker
MHC-1 (upper panel; original magnification, ×10). The drawn lines
show the margin of the primary tumor masses and the migrated
tumor cells away from the margin. Sunitinib treatment resulted
in a significantly increased migration of cells from the main tumor
mass (P < .0001). Treatment with vatalanib and AMD3100 re-
sulted in a statistically significant reduction in the tumor cell migra-
tion compared to vehicle-treated tumor (P < .0001) (lower panel).
*P < .05.
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may be mediated by the alternative angiogenic pathways including
SDF-1α–CXCR4 pathway and by the mobilization of BM progenitor
cells due to the release of G-CSF from the tumors. G-CSF is known to
be a strong mobilizer of BM cells to the peripheral blood. However,
sunitinib treatment increased the expression of proangiogenic growth
factors such as SDF-1α, angiopoietin-1 and angiopoietin-2, angio-
genin, MMP-2, Tie-1 and Tie-2, PDGF-AA, EGF, and HIF-1α.
We also observed a greater magnitude of tumor invasion as measured
by the distance traveled byMHC-1–positive cells from the main tumor
mass, following treatment with sunitinib. Our results are in agreement
with preclinical studies that have indicated an increase in the metastatic
potential of tumor cells after treatment with sunitinib [47]. AMD3100
treatment led to a decrease in the expression of most proangiogenic
factors and an increase in angiostatin, an antiangiogenic protein. These
changes could explain the reduction in angiogenesis and tumor growth
following AMD3100 treatment. There was also a significant reduction
in tumor cell invasion as seen by decreased MHC-1–positive cells away
from the main tumor mass.
AMD3100 is a CXCR4 receptor antagonist and is known to in-
hibit SDF-1α binding to this receptor and related signal transduction
[30]. The CXCR4 receptor is expressed on glioma cells and is known
to play a role in their migration and invasion [31–37]. There is an
experimental evidence to support the role of CXCR4/SDF-1α in
glioma angiogenesis [31,37,38]. Our results indicate that the inhibi-
tion of CXCR4 receptor in gliomas could potentially lead to reduced
tumor growth, angiogenesis, and invasion. Though AMD3100 re-
duced angiogenesis and U251 tumor growth, there was an increase
in expression of some of the proangiogenic factors including MMP-2
and HIF-1α. Both MMP-2 and HIF-1α are known to promote
angiogenesis through the VEGF pathway [39,40]. Our results in-
dicate that, in addition to the VEGF pathway, CXCR4-mediated
angiogenesis may also play an important role in angiogenesis and
tumor growth.
Currently, there are many antiangiogenic agents under investiga-
tion in phase I/II clinical trials for the treatment of high-grade glioma
[41]. Many of the novel agents have failed to show meaningful clini-
cal benefit. Recent clinical trials using sunitinib in patients with re-
current high-grade glioma have failed to show any objective evidence
of tumor control [42–44]. Similarly, vatalanib has been tested in
pilot clinical trials. Although the drug was well tolerated, it was shown
to have limited efficacy in a treatment of newly diagnosed GBM [45].
Though many patients demonstrate an initial clinical response to anti-
angiogenic therapy, no significant improvement in survival has been
noted. Treatment resistance to a particular antiangiogenic drug could
be mediated by non–VEGF-related angiogenesis. On the basis of our
preclinical results, one of the potential targets for antiangiogenic ther-
apy in glioma could be CXCR4 receptor–mediated vasculogenesis.
Not only did CXCR4 receptor decreased tumor vascularization
and growth, it also reduced tumor cell invasion and migration. In
fact, AMD3100 has been previously shown to inhibit tumor growth
by increasing apoptosis and decreasing proliferation in a preclinical
model [46].
The study has following limitations: 1) The uniformity in the
tumor size across the sample at the beginning of the treatment was
not determined. However, our extensive experience in working with
this model gave us sufficient information about the growth profile
of the tumors. At day 7 after implantation, tumors are expected to
exhibit a uniform growth and size across the sample, and the life
expectancy of an untreated animal carrying tumor of this size is about
28 to 35 days after implantation [10]. 2) We did not test the expres-
sion level of proangiogenic factors in tumors before the beginning
of the treatment. Tissues collected from vehicle-treated tumor-bearing
animals were used as a proper indicator of the basal expression levels
of proangiogenic factors in the untreated tumors.
Conclusion
In conclusion, our results indicate that AMD3100 has a significant
inhibitory effect on the growth and angiogenesis in U251 tumors,
as measured by MRI and protein expression levels. Vatalanib treat-
ment paradoxically promoted angiogenesis and tumor growth in the
Figure 6. Co-expression of CD44, MMP-2, and vWF in the vicinity of MHC-1–positive cells, following antiangiogenic treatment. Upper
panel: Double staining with anti–MHC-1 (green) and anti–MMP-2 (red) antibodies shows correlation between the two markers of tumor
invasion. Lower panel: Double staining with anti-vWF (green) and anti-CD44 (red) antibodies showed CD44-positive cells lining the
vWF-positive areas, indicating possible incorporation of tumor cells into new vessels (yellow arrow).
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U251 animal model. Although sunitinib treatment resulted in in-
hibition of U251 tumor growth, there was no uniform inhibition
of the expression of proangiogenic factors. Our results add to the
growing body of evidence that implicates the importance of non–
VEGF-related pathways in glioma angiogenesis and vasculogenesis.
Future clinical trials are still necessary to test the antitumor efficacy
of AMD3100 in the treatment of high-grade glioma.
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